Enveric Biosciences Inc (ENVB)

US · Healthcare · Biotechnology

$1.59+6.71%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-3.0M

EPS

$-0.76

Market cap

$6.4M

Forward P/E

23.1

P/B

0.80

Book value

$2.05

EPS (TTM)

$-12.18

52-week high

$13.25

52-week low

$1.17

50-day MA

$1.42

200-day MA

$2.65

Beta

1.11

Analysts rate Enveric Biosciences Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $10.00.

Insiders

8.89%

Institutions

12.02%

Fund	Stake
Sio Capital Management, LLC	4.02%
AdvisorShares Investments, LLC	0.79%
Geode Capital Management, LLC	0.72%
Citadel Advisors Llc	0.31%
UBS Group AG	0.08%
Tower Research Capital LLC	0.02%
JONES FINANCIAL COMPANIES LLLP	0.02%
Integrated Wealth Concepts LLC	0.02%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Enveric Biosciences Inc — free to start.

Data updated 2026-09-18.